Cure Ventures
May Han is a seasoned professional with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as a Partner at Cure Ventures since September 2021, May has previously held key positions, including Director of Project Management at Novartis from October 2013 to September 2021, and Program Leader and Director of Preclinical Development at AVEO Oncology from October 2003 to October 2013. Earlier career experiences include roles as Scientist II at Millennium Pharmaceuticals Inc. and postdoctoral research at Yale University and Rockefeller University. May's academic credentials include a Ph.D. in Biophysics and Biochemistry from Yale University and a BS in Biochemistry from Peking University.
Cure Ventures
Cure Ventures is a venture firm focused on investing in the life sciences and medical technologies. We aim to propel novel cures to market by discovering and enabling biotechnology, pharmaceutical, medical device, and medtech firms with exceptional growth potential committed to addressing unmet medical needs for global patient targets.